Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

  title={Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum},
  author={Gajanan N. Sapkal and Pragya Dhruv Yadav and Raches Ella and Gururaj Deshpande and Rima R Sahay and Nivedita Gupta and Vadrevu Krishna Mohan and Priya Abraham and Samiran Panda and Balram Bhargava},
We performed the plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape. 
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1-CoV-2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively. Expand
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) proteinExpand
An Update on the Leading COVID-19 Vaccines
A literature review was performed with the objective to evaluate vaccine efficacy, safety and technology of the COVID-19 vaccines that have reached phase III of clinical development. Expand
Emerging SARS-CoV-2 variants of concern and potential intervention approaches
The major variant of concerns (VOCs) have shared mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins, mostly on the S1 unit and resulted in higherExpand
Comparison of the pathogenicity and virus shedding of SARS CoV-2 VOC 202012/01 and D614G variant in hamster model
SARS-CoV-2 VOC 202012/01 infected hamsters demonstrated high viral RNA shedding through the nasal secretions and significant body weight loss with mild lung pathology compared to the D614G variant. Expand
Efficacy of Vaccine and Administration of Vaccine for all the Individuals against SARS-CoV-19 and the Variants
The efficacy of different designed drug for SARS-CoV-2 has been much of debate from the approval and till date after roll out. The data released from WHO, CDC, PHE and ICMR is used to analysis andExpand
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
In vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern, and other strains are summarized to provide guidance for the treating physician. Expand
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
Why most COVID-19 vaccines target the S protein, update the progress of research regarding S protein-related COIDs, review the latest studies concerning the effects of S protein variants on COIDS, and propose certain strategies to deal with SARS-CoV-2 variants. Expand
Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
This review summarized and analyzed the progress of vaccines against SARS- coV, MERS-CoV, and Sars- CoV, including inactivated vaccines, live attenuated vaccines, subunit vaccines, nucleic acid vaccines, and viral vector vaccines. Expand
COVID-19 Vaccines in Patients With Chronic Liver Disease
Patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19, and trials to assess the safety and efficacy of the COVID vaccines are under way and are likely to provide valuable insight into this matter. Expand


SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma and suggest that SARS has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed. Expand
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients
In the early stages of infection, the NAb response was observed with variable antibody kinetics, and neutralization assays can be used for titration of NAb in recovered/vaccinated or infected COVID-19 patients. Expand
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
An interactive visualization and open analysis pipeline is presented to facilitate use of the dataset for vaccine design and functional annotation of mutations observed during viral surveillance. Expand
KM,Jogdand H,et al.A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152medRxiv 2020.12.11.20210419
  • 2021
New variant of SARS-CoV-2 in UK causes surge of COVID-19
  • T. Kirby
  • Medicine
  • The Lancet Respiratory Medicine
  • 2021
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
It is found that a substantial number of mutations to the RBD are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. Expand
    A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152medRxiv
      The bar represents the mean and standard deviation of the respective sera
      • /India/2020Q111 (heterologous unclassified cluster)